A study by the University of Barcelona has discovered why the two main types of lung cancer—adenocarcinoma of the lung and ...
Morning Overview on MSN
A bispecific antibody beat a standard immunotherapy regimen head-to-head in squamous lung cancer at ASCO 2026
A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared ...
Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...
Predisposition to ALL and Solid Tumors Rather Than Bone Marrow Failure in FANCM-Associated Fanconi Anemia The SCRUM-MONSTAR GOZILA study is a nationwide, plasma-based molecular profiling project using ...
Squamous cell carcinoma of the lung is linked to smoking and requires early detection and accurate staging for effective treatment. Diagnosis involves imaging and biopsy, with the TNM system used to ...
Squamous cell carcinoma treatment varies by stage, involving surgery, radiation, and systemic therapies based on cancer progression and patient health. Stage 1 focuses on tumor removal, Stage 2 ...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...
Esophageal squamous cell carcinoma (ESCC) represents a significant global health burden characterized by a high mortality ...
Corrixr Therapeutics, a pre-clinical genetic medicine company targeting lung, head & neck, and esophageal squamous cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results